Amit Sanyal, MD: A Clinician’s Perspective

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Jul

Today In Oncology

Amit Sanyal, MD: A Clinician’s Perspective

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

People With Acromegaly Face Elevated Cancer Risk, Study Finds

Resectable NSCLC Overall Survival With Neoadjuvant Nivolumab Plus Chemotherapy

Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers

New Guidelines on Comprehensive Biomarker Testing of Bronchoscopic Biopsies

MRD-Guided Therapy With Ibrutinib-Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia